Anti Infective Agents Impact in COVID-19 Pneumonia
Anti Infective Agents Impact in COVID-19 Pneumonia
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key
 agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et
 al. proposed the combination regimen with azithromycin. However only one study reported the
 interest of azithromycin alone.

 Retrospective study reporting the impact of the anti-infective agents used during the
 pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.
Inclusion Criteria:

 -  aged over 18 years old

 -  hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry,

 -  admitted outside an intensive care unit, in a medicine ward

 Exclusion Criteria:

 -  patient opposed to data collected, or who could not consent because of a serious
 presentation of the pneumonia